AI Article Synopsis
- - Understanding T-cell responses is vital for developing effective COVID-19 therapies and vaccines, focusing on spike-specific CD8 T cells from those vaccinated.
- - The study found that the BNT162b2 mRNA vaccine boosts the production of CD8 T cells that can respond to variants like BA.1, though their diversity diminishes over time.
- - At 4 weeks post-second vaccination, a significant T-cell subpopulation expressing Granzyme A, Granzyme B, and Perforin was observed; however, this response decreased by 12 weeks, indicating the need for strategies to enhance T-cell longevity and efficacy against new variants.
Article Abstract
Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8 T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8 T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8 T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8 T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845949 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.1081047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!